2020
Characterizing patterns of disease progression in patients with genitourinary cancers treated with immune checkpoint inhibitors.
Patel V, Qin Q, Mellgard G, Parikh A, Wang B, Alerasool P, Garcia P, Jaladanki S, Leiter A, Carroll E, Brooks D, Shimol J, Eisenberg E, Gallagher E, Galsky M, Oh W, Tsao C. Characterizing patterns of disease progression in patients with genitourinary cancers treated with immune checkpoint inhibitors. Journal Of Clinical Oncology 2020, 38: 482-482. DOI: 10.1200/jco.2020.38.6_suppl.482.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsPatterns of disease progressionRenal cell carcinomaUrothelial carcinomaCheckpoint inhibitorsCancer treated with immune checkpoint inhibitorsTreated with immune checkpoint inhibitorsDisease progressionImmune checkpoint inhibitor doseSites of disease involvementAdvanced urothelial carcinomaLocation of metastasesSite of diseaseFisher's exact testReduced rates of hospitalizationLoss of appetiteRates of hospitalizationCell carcinomaDisease involvementClinical factorsExact testQuality-of-lifeMedical historyPatientsHospitalization details
2018
Phenotypes of organ involvement in sarcoidosis
Schupp J, Freitag-Wolf S, Bargagli E, Mihailović-Vučinić V, Rottoli P, Grubanovic A, Müller A, Jochens A, Tittmann L, Schnerch J, Olivieri C, Fischer A, Jovanovic D, Filipovic S, Videnovic-Ivanovic J, Bresser P, Jonkers R, O'Reilly K, Ho L, Gaede K, Zabel P, Dubaniewicz A, Marshall B, Kieszko R, Milanowski J, Günther A, Weihrich A, Petrek M, Kolek V, Keane M, O'Beirne S, Donnelly S, Haraldsdottir S, Jorundsdottir K, Costabel U, Bonella F, Wallaert B, Grah C, Peroš-Golubičić T, Luisetti M, Kadija Z, Pabst S, Grohé C, Strausz J, Vašáková M, Sterclova M, Millar A, Homolka J, Slováková A, Kendrick Y, Crawshaw A, Wuyts W, Spencer L, Pfeifer M, Valeyre D, Poletti V, Wirtz H, Prasse A, Schreiber S, Krawczak M, Müller-Quernheim J. Phenotypes of organ involvement in sarcoidosis. European Respiratory Journal 2018, 51: 1700991. PMID: 29371378, DOI: 10.1183/13993003.00991-2017.Peer-Reviewed Original ResearchConceptsOrgan involvementIntrathoracic lymph node involvementAbdominal organ involvementLymph node involvementEuropean multicentre studySystemic granulomatous diseaseNew clinical phenotypeHitherto unknown etiologyAcute onsetExtrapulmonary involvementNode involvementSkin involvementFemale patientsMulticentre studyDisease involvementUnknown etiologyCaucasian patientsGranulomatous diseaseHomogenous cohortSarcoidosisPatientsClinical phenotypeStudy centersStandardised protocolDisease phenotype
2016
Cranial nerve involvement in Charcot–Marie–Tooth Disease
Das N, Kandalaft S, Wu X, Malhotra A. Cranial nerve involvement in Charcot–Marie–Tooth Disease. Journal Of Clinical Neuroscience 2016, 37: 59-62. PMID: 27884603, DOI: 10.1016/j.jocn.2016.10.049.Peer-Reviewed Original ResearchConceptsCranial nerve involvementNerve involvementTooth diseaseCharcot-MarieFacial muscle weaknessSpinal nerve rootsSkull base foraminaGroup of disordersForms of HMSNNerve findingsRight medianClinical featuresClinical presentationCauda equineDisease involvementMuscle weaknessNerve rootsSymmetric enlargementTrigeminal neuralgiaTrigeminal nerveFacial nervePes cavusEmergency roomAbsent responseRare disorderClinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides
Foss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clinical Lymphoma Myeloma & Leukemia 2016, 16: 637-643. PMID: 27637428, DOI: 10.1016/j.clml.2016.08.009.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaFolliculotropic mycosis fungoidesPrevious systemic therapyMycosis fungoidesDisease involvementCutaneous tumorsTumor stageSystemic therapyRefractory cutaneous T-cell lymphomaSubtypes of CTCLSafety of romidepsinObjective response ratePhase II studyAggressive disease courseReview of diagnosisT-cell lymphomaHistone deacetylase inhibitorsII studyComposite endpointDisease courseHistology reportsClinical efficacyUncommon subtypeFavorable outcomePatients
1986
Prognostic indicators in diffuse large-cell (histiocytic) lymphoma
Todd M, Portlock C, Farber L, Holford T, Bertino J. Prognostic indicators in diffuse large-cell (histiocytic) lymphoma. International Journal Of Radiation Oncology • Biology • Physics 1986, 12: 593-601. PMID: 2422144, DOI: 10.1016/0360-3016(86)90068-4.Peer-Reviewed Original ResearchConceptsDiffuse large cell lymphomaLarge cell lymphomaPrognostic groupsSystemic symptomsPrognostic indicatorAnn Arbor staging systemBone marrow involvementBulk of diseaseLactic dehydrogenaseDiffuse histiocytic lymphomaAnn Arbor classificationStage of diseaseReliable prognostic indicatorChemotherapy clinical trialsLukes-Collins classificationSerum lactic dehydrogenaseMarrow involvementOverall survivalCombination chemotherapyPrognostic factorsDisease involvementPathological criteriaStaging systemSpecific therapyHistiocytic lymphoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply